201 related articles for article (PubMed ID: 21756166)
1. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
2. Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.
Merelli A; Caltana L; Girimonti P; Ramos AJ; Lazarowski A; Brusco A
Neurotox Res; 2011 Aug; 20(2):182-92. PubMed ID: 21116766
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin and the hypoxic brain.
Marti HH
J Exp Biol; 2004 Aug; 207(Pt 18):3233-42. PubMed ID: 15299044
[TBL] [Abstract][Full Text] [Related]
4. [Erythropoietin--a new therapy in cerebral ischemia?].
Kalialis LV; Olsen NV
Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro.
Liu R; Suzuki A; Guo Z; Mizuno Y; Urabe T
J Neurochem; 2006 Feb; 96(4):1101-10. PubMed ID: 16417583
[TBL] [Abstract][Full Text] [Related]
6. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.
Merelli A; Czornyj L; Lazarowski A
Curr Pharm Des; 2013; 19(38):6791-801. PubMed ID: 23530506
[TBL] [Abstract][Full Text] [Related]
8. Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.
Castañeda-Arellano R; Feria-Velasco AI; Rivera-Cervantes MC
Neurosci Lett; 2014 Nov; 583():16-20. PubMed ID: 25219375
[TBL] [Abstract][Full Text] [Related]
9. Intranasal erythropoietin therapy in nervous system disorders.
Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
[TBL] [Abstract][Full Text] [Related]
10. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia.
Yu YP; Xu QQ; Zhang Q; Zhang WP; Zhang LH; Wei EQ
Neurosci Lett; 2005 Oct; 387(1):5-10. PubMed ID: 16054296
[TBL] [Abstract][Full Text] [Related]
11. [Erythropoietin and neuroprotection].
Chatagner A; Hüppi PS; Ha-Vinh Leuchter R; Sizonenko S
Arch Pediatr; 2010 Sep; 17 Suppl 3():S78-84. PubMed ID: 20728813
[TBL] [Abstract][Full Text] [Related]
12. The role and regulation of hypoxia-inducible factor-1alpha expression in brain development and neonatal hypoxic-ischemic brain injury.
Fan X; Heijnen CJ; van der Kooij MA; Groenendaal F; van Bel F
Brain Res Rev; 2009 Dec; 62(1):99-108. PubMed ID: 19786048
[TBL] [Abstract][Full Text] [Related]
13. Expression of the gene encoding the pro-apoptotic BNIP3 protein and stimulation of hypoxia-inducible factor-1alpha (HIF-1alpha) protein following focal cerebral ischemia in rats.
Althaus J; Bernaudin M; Petit E; Toutain J; Touzani O; Rami A
Neurochem Int; 2006 Jun; 48(8):687-95. PubMed ID: 16464515
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
Acs G; Xu X; Chu C; Acs P; Verma A
Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
[TBL] [Abstract][Full Text] [Related]
16. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC; Sosa-Teste I
ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
[TBL] [Abstract][Full Text] [Related]
17. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas.
Dagnon K; Pacary E; Commo F; Antoine M; Bernaudin M; Bernaudin JF; Callard P
Clin Cancer Res; 2005 Feb; 11(3):993-9. PubMed ID: 15709164
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury.
Celik M; Gökmen N; Erbayraktar S; Akhisaroglu M; Konakc S; Ulukus C; Genc S; Genc K; Sagiroglu E; Cerami A; Brines M
Proc Natl Acad Sci U S A; 2002 Feb; 99(4):2258-63. PubMed ID: 11854521
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
20. Heat acclimation increases hypoxia-inducible factor 1alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice.
Shein NA; Horowitz M; Alexandrovich AG; Tsenter J; Shohami E
J Cereb Blood Flow Metab; 2005 Nov; 25(11):1456-65. PubMed ID: 15902197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
